The document discusses interchangeable biosimilars and the Arthritis Foundation's position on their substitution. The Foundation supports a policy requiring that the prescribing physician be notified and communicated with about any substitution of an interchangeable biosimilar for the originally prescribed biologic medication. This is important considering the complex nature and specialized use of biologics to treat serious medical conditions. Prescriber communication is seen as essential to ensure the safe use of interchangeable biosimilars and proper management of the patient's treatment. The presentation provides background on the Foundation's advocacy in this area and the increasing state-level legislative activity around biosimilar substitution policies.